Please ensure Javascript is enabled for purposes of website accessibility

Why Biogen Stock Rose 14.7% in February

By Adria Cimino - Mar 3, 2020 at 4:20PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors cheer as Biogen wins a patent ruling involving its blockbuster multiple sclerosis drug.

What happened

Shares of Biogen (BIIB 3.28%) rose 14.7% in February, according to data provided by S&P Global Market Intelligence, after the company won a patent ruling concerning its blockbuster multiple sclerosis drug.

In a case brought by generic-drug maker Mylan (MYL), the U.S. Patent and Trademark Office's patent trial and appeal board ruled in Biogen's favor. That means Biogen's Tecfidera won't face competition until patent expiration in 2028 -- unless a Mylan appeal or other separate patent challenges result in a different decision.

White pills spill out of a bottle of prescription medication.

Image source: Getty Images.

So what

In the fourth quarter, Tecfidera accounted for 40% of Biogen's product revenues, so news upholding its patent, and therefore blocking generic competition, is positive. This gives Biogen time to ramp up sales of its new MS drug, Vumerity, in the coming quarters. A fumarate drug like Tecfidera, Vumerity offers the same efficacy with fewer side effects.

Now what

Now the task facing Biogen is transferring patients from Tecfidera to Vumerity. The U.S. Food and Drug Administration approved Vumerity in October, and the drug generated $5 million in its first quarter on the market. So, it has a way to go before it can compensate for declines in Tecfidera once patent protection is lost. Investors will be watching the progression of Vumerity sales in the coming quarters and should monitor news from other patent cases involving Tecfidera. Another case with Mylan is currently unfolding in West Virginia.

An even bigger catalyst for Biogen in the coming months will likely be news linked to aducanumab, the investigational Alzheimer's treatment the company revived in the fall after ending the program earlier in the year. New data boosted optimism about the drug's efficacy, and the biotech company said it would submit aducanumab to the FDA for review early this year.

Biogen's shares have given up some of the February gain and are now up 6.4% so far this year. But any further good news on the Tecfidera patent, progress in Vumerity sales, and optimism about the company's Alzheimer's treatment may send the biotech stock higher.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Biogen Inc. Stock Quote
Biogen Inc.
$210.63 (3.28%) $6.69
Viatris Inc. Stock Quote
Viatris Inc.

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/02/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.